Home » Stocks » ARGX

Argenx SE (ARGX)

Stock Price: $302.36 USD -13.73 (-4.34%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 15.88B
Revenue (ttm) 44.42M
Net Income (ttm) -645.03M
Shares Out 51.31M
EPS (ttm) -12.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $302.36
Previous Close $316.09
Change ($) -13.73
Change (%) -4.34%
Day's Open 311.40
Day's Range 301.29 - 311.40
Day's Volume 139,566
52-Week Range 212.66 - 382.15

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

July 22, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, toda...

5 days ago - GlobeNewsWire

July 14, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, toda...

1 week ago - GlobeNewsWire

Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvement s in strength and quality of life measures in g eneralized m yasthenia g ravis (gMG )

1 month ago - GlobeNewsWire

argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate.

1 month ago - Zacks Investment Research

Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting cusatuzumab. The pair first came together to develop th...

Other stocks mentioned: JNJ
1 month ago - Benzinga

Regulated Information/Inside Information

1 month ago - GlobeNewsWire

June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today...

1 month ago - GlobeNewsWire

June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today...

1 month ago - GlobeNewsWire

Shares of argenx (NASDAQ:ARGX) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 60.68% year over year to ($0.81), which may not compare to the estimat...

2 months ago - Benzinga

Japanese Marketing Authorization Application (J-MAA) for efgartigimod accepted for review by Japan's Pharmaceuticals and Medical Device Agency (PMDA) for generalized myasthenia gravis (gMG)

2 months ago - GlobeNewsWire

argenx (NASDAQ:ARGX) releases its next round of earnings this Friday, May 14. Here is Benzinga's essential guide to argenx's Q1 earnings report.

2 months ago - Benzinga

May 1 1 , 20 2 1 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer...

2 months ago - GlobeNewsWire

May 7, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today ...

2 months ago - GlobeNewsWire

April 28, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, tod...

2 months ago - GlobeNewsWire

Pharmaceutical stocks are a sector with unique success factors. One factor is developing blockbuster drugs.

Other stocks mentioned: BHVN, BMRN, MRTX, NVO, NVS
4 months ago - InvestorPlace

Shares of argenx (NASDAQ:ARGX) fell 3.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 60.08% year over year to ($4.21), which missed the es...

4 months ago - Benzinga

- Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG)

4 months ago - GlobeNewsWire

The FDA has accepted for review Argenx SE's (NASDAQ: ARGX) marketing application seeking approval for intravenous (IV) efgartigimod, for the treatment of generalized myasthenia gravis (gMG). Myasthenia ...

4 months ago - Benzinga

February 25, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, ...

5 months ago - GlobeNewsWire

Regulated information

5 months ago - GlobeNewsWire

Regulated information — Inside information

5 months ago - GlobeNewsWire

Regulated information — Inside information

5 months ago - GlobeNewsWire

-No observed elevation of cholesterol markers related to treatment with efgartigimod

5 months ago - GlobeNewsWire

Regulated information — Inside information

5 months ago - GlobeNewsWire

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up...

Other stocks mentioned: EYPT, GILD, GRCL, INO, LLY, PRTK, ZLAB
6 months ago - Seeking Alpha

Breda, the Netherlands – Jan. 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, to...

6 months ago - GlobeNewsWire

January 4, 2021 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseas...

6 months ago - GlobeNewsWire

November 23, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune dise...

8 months ago - GlobeNewsWire

BREDA, the Netherlands and GHENT, Belgium, Nov. 17, 2020 /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe au...

8 months ago - PRNewsWire

November 9, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disea...

8 months ago - GlobeNewsWire

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q3 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Shares of argenx (NASDAQ:ARGX) decreased 6.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 450.00% year over year to ($3.96), which missed ...

9 months ago - Benzinga

- Biologics License Application (BLA) for efgartigimod in generalized myasthenia gravis (gMG) on track to be submitted to U.S. Food and Drug Administration (FDA) by end of 2020 -

9 months ago - GlobeNewsWire

October 15, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disea...

9 months ago - GlobeNewsWire

Argenx: Competitive Positioning In The GMG Space

9 months ago - Seeking Alpha

September 2, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune d...

10 months ago - GlobeNewsWire

August 4, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune dise...

11 months ago - GlobeNewsWire

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

July 30, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disea...

11 months ago - GlobeNewsWire

On Thursday, July 30, argenx (NASDAQ: ARGX) will release its latest earnings report.

11 months ago - Benzinga

argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Regulated information

1 year ago - GlobeNewsWire

Regulated information — Inside information

1 year ago - GlobeNewsWire

Regulated information — Inside information

1 year ago - GlobeNewsWire

argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.

1 year ago - Zacks Investment Research

Regulated information — Inside information

1 year ago - GlobeNewsWire

About ARGX

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indic... [Read more...]

Industry
Biotechnology
IPO Date
May 18, 2017
CEO
Tim Van Hauwermeiren
Employees
336
Stock Exchange
NASDAQ
Ticker Symbol
ARGX
Full Company Profile

Financial Performance

In 2020, Argenx SE's revenue was 36.43 million, a decrease of -47.80% compared to the previous year's 69.78 million. Losses were -528.92 million, 224.6% more than in 2019.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 17 analysts, the average rating for Argenx SE stock is "Buy." The 12-month stock price forecast is 342.47, which is an increase of 13.27% from the latest price.

Price Target
$342.47
(13.27% upside)
Analyst Consensus: Buy